Rachael McCormack

Lifetime cardiovascular management of patients with previous Kawasaki disease

H. Gray, M. Levin, J. Burns, 2019, Heart.

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

A. Walker, N. Klein, J. Standing, 2023, Trials.